When Xarelto was first introduced to the market in 2011, it was marketed as being a better and more convenient blood-thinner than Wafarin. Xarelto was approved because it was intended to reduce the risk of patients having blood clots after a surgery, particularly a knee surgery or a hip surgery. Xarelto was also supposed to reduce the risk of patients having a stroke, especially those with non-valvular atrial fibrillation. Xarelto was advertised as being better because it did not come with a requirement of blood monitoring and patients just had to take one dose.
The patients who took Warfarin had to continuously test and monitor their blood. The doctors wanted to ensure the medication was working well.
When patients were prescribed Xarelto, one of the things they were told was that they did not have to undergo any blood monitoring. However, many researchers feel that patients who have taken Xarelto would have greatly benefited from blood monitoring. All of the patients who had excessive bleeding probably would have been notified of those risks before it happened if blood monitoring was a requirement.
Although the newer anticoagulants only require patients to take one dose, this kind of convenience will have an impact on the safety of the patients. Xarelto and all of its “convenient” factors is likely all for advertising and marketing, it does not really market what is best for the people who actually take the drug.
If you or a loved one suffered from severe bleeding after taking Xarelto, please contact the Levensten Law Firm at 215-545-5600 or on our home page, or at www.xareltoinjurylawyer.com to learn how to file a claim for compensation for your injuries.